Hjem › Neuroendokrine tumorer › Texas
Neuroendokrine tumorer kliniske forsøg i Texas
11 studier for Neuroendokrine tumorer søger deltagere på steder i Texas.
Byer i Texas
Officiel studietekst (engelsk)
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Texas Oncology- Baylor Charles A. Sammons Cancer Center, Dallas
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT06943755A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- Investigative Site, Houston
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06881992Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- University of Texas - MD Anderson Cancer Center, Houston
RekruttererFase 1
24 Months – 18 Years · Alle køn · Opdateret 25. sep. 2026 · NCT06441331Project: Every Child for Younger Patients With Cancer
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- og 12 flere
RekruttererObservationsstudie
Op til 25 år · Alle køn · Opdateret 25. aug. 2026 · NCT02402244A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Austin
- Crinetics Study Site, Houston
- Crinetics Study Site, Irving
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT07129252A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 27. maj 2026 · NCT03093116Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
- Clinical Research Institute at Methodist Health System, Dallas
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 20. mar. 2026 · NCT04090034Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- UT Southwestern Medical Center, Dallas
RekruttererFase 4
Alder 18 til 64 · Alle køn · Opdateret 22. jan. 2026 · NCT04373564A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 11. dec. 2025 · NCT06943521SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2025 · NCT06805825Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.